A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive Impairment
Status:
Completed
Trial end date:
2004-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this follow-up study is to assess the long-term safety and tolerability of
galantamine in individuals with mild cognitive impairment who participated in a previous
study with galantamine
Phase:
Phase 3
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.